A subset of heart failure patients treated with cardiac resynchronization therapy (CRT) did not demonstrate a significant improvement in exercise capacity measured by peak VO2 when compared to a control group, researchers reported in a late-breaking clinical trial session at the American Heart Association’s Scientific Sessions 2007.In the Resynchronization Therapy in Normal QRS trial (RethinQ), scientists implanted patients with a CRT device and randomized them into a treatment group of 85 and a control group 87. The average age was 58 years.
